Clinical Trial Update: Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the combination of ipatasertib, pertuzumab, and trastuzumab in advanced HER2-positive, PI3KCA-mutant metastatic breast cancer has been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Pi3kca-mutant Breast Cancer

Drugs mentioned

• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)
• ipatasertib (ipatasertib)

Snippet

Sponsor: SOLTI Breast Cancer Research Group | Conditions: Metastatic Breast Cancer | Phase 1 | Status: COMPLETED